Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma

Habitat escalated adaptive therapy (HEAT): a phase 2 trial utilizing radiomic habitat-directed and genomic-adjusted radiation dose (GARD) optimization for high-grade soft tissue sarcoma

Abstract Background Soft tissue sarcomas (STS), have significant inter- and intra-tumoral heterogeneity, with poor response to standard neoadjuvant radiotherapy (RT). Achieving a favorable pathologic response (FPR ≥ 95%) from RT is associated with improved patient outcome. Genomic adjusted radiation...

Full description

Bibliographic Details
Main Authors: Arash O. Naghavi, J. M. Bryant, Youngchul Kim, Joseph Weygand, Gage Redler, Austin J. Sim, Justin Miller, Kaitlyn Coucoules, Lauren Taylor Michael, Warren E. Gloria, George Yang, Stephen A. Rosenberg, Kamran Ahmed, Marilyn M. Bui, Evita B. Henderson-Jackson, Andrew Lee, Caitlin D. Lee, Ricardo J. Gonzalez, Vladimir Feygelman, Steven A. Eschrich, Jacob G. Scott, Javier Torres-Roca, Kujtim Latifi, Nainesh Parikh, James Costello
Format: Article
Language:English
Published: BMC 2024-04-01
Series:BMC Cancer
Subjects:
Sarcoma
Soft tissue sarcomas
Radiomic
Pathology
Genomic
Neoadjuvant
Online Access:https://doi.org/10.1186/s12885-024-12151-7

Internet

https://doi.org/10.1186/s12885-024-12151-7

Similar Items